Can-Fite BioPharma Ltd.CANFNYSE
Loading
Net Income Growth TrendStable
Percentile Rank46
Year-over-Year Change
Year-over-year net income growth rate
Latest
0.00%
↑ 100% vs avg
Percentile
P46
Within normal range
Streak
1 qtr
Consecutive growthStable
Average
-66.49%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | -24.29% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.86% |
| Q2 2024 | 0.00% |
| Q1 2024 | -19.76% |
| Q4 2023 | 6.24% |
| Q3 2023 | -5.51% |
| Q2 2023 | 30.07% |
| Q1 2023 | 19.19% |
| Q4 2022 | -21.06% |
| Q3 2022 | -0.33% |
| Q2 2022 | 5.04% |
| Q1 2022 | 37.79% |
| Q4 2021 | -21.12% |
| Q3 2021 | -5.62% |
| Q2 2021 | -71.41% |
| Q1 2021 | 48.31% |
| Q4 2020 | -41.09% |
| Q3 2020 | 33.86% |
| Q2 2020 | 10.34% |
| Q1 2020 | -148.68% |
| Q4 2019 | 40.77% |
| Q3 2019 | 3.69% |
| Q2 2019 | -67.09% |
| Q1 2019 | 46.57% |
| Q4 2018 | -1837.29% |
| Q3 2018 | 85.77% |
| Q2 2018 | 27.72% |
| Q1 2018 | -60.20% |
| Q4 2017 | -114.03% |
| Q3 2017 | 76.20% |
| Q2 2017 | -64.29% |
| Q1 2017 | 27.01% |
| Q4 2016 | 21.42% |
| Q3 2016 | -62.82% |
| Q2 2016 | 9.96% |
| Q1 2016 | -664.30% |
| Q4 2015 | 109.08% |
| Q3 2015 | -70.55% |